Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about RHHVF
Recent news which mentions RHHVF
< Previous
1
2
3
4
5
Next >
FDA Approves First Injectable Eye Medicine For Vision Loss Disorder - Genentech's Vabysmo
January 31, 2022
Tickers
RHHBF
RHHBY
RHHVF
Tags
RHHVF
Market News
Health Care
From
Benzinga
Genentech's Evrysdi Application Under FDA Priority Review For Use In Babies Below 2 Months
January 25, 2022
Tickers
RHHBF
RHHBY
RHHVF
Tags
Health Care
Market News
RHHVF
From
Benzinga
CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply
January 12, 2022
Tickers
BIIB
ESALF
ESALY
LLY
Tags
Movers
Health Care
Market News
From
Benzinga
Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases
December 20, 2021
Tickers
LCTX
RHHBF
RHHBY
RHHVF
Tags
Market News
RHHVF
Contracts
From
Benzinga
Novartis Launches New Share Buyback Program Of Up To $15B
December 16, 2021
Tickers
NVS
RHHBF
RHHBY
RHHVF
Tags
Market News
RHHVF
Health Care
From
Benzinga
After Roche Walks Away, Atea Puts Break On Late-Stage COVID-19 Oral Antiviral Trial
December 15, 2021
Tickers
AVIR
RHHBF
RHHBY
RHHVF
Tags
News
General
Phase 3 Trial
From
Benzinga
Roche's Polivy Combo Boosts Survival In Early-Stage Lymphoma Patients
December 14, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
Health Care
Movers
Diffuse Large B/Cell Lymphoma
From
Benzinga
Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings
December 13, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
Phase 2 Trial
Briefs
News
From
Benzinga
Infinity Pharma Shares Updated Eganelisib Combo Therapy In Breast Cancer Trial
December 10, 2021
Tickers
BMY
INFI
RHHBF
RHHBY
Tags
Phase 2 Trial
INFI
Briefs
From
Benzinga
Roche Posts Encouraging Follow-up Data From Tiragolumab/Tecentriq Trial In Lung Cancer
December 10, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
Phase 2 Trial
Biotech
RHHBY
From
Benzinga
Europe Approves Roche's Tocilizumab For Patients With Severe COVID-19
December 07, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
General
News
Briefs
From
Benzinga
Immunocore' ImmTAC Candidate Shows Early Response In Ovarian And Head & Neck Cancer Patients
December 06, 2021
Tickers
IMCR
RHHBF
RHHBY
RHHVF
Tags
Small Cap
RHHVF
Market News
From
Benzinga
Biden's New COVID-19 Plan Includes Reimbursement For Over The Counter, At-Home COVID Tests
December 03, 2021
Tickers
ABT
BDX
CI
CVS
Tags
ABT
LHDX
Regulations
From
Benzinga
Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact
December 02, 2021
Tickers
ALPMF
ALPMY
NVS
RHHBF
Tags
Market News
RHHVF
ALPMF
From
Benzinga
Roche's Gavreto Conditionally Approved In Europe For RET Fusion-Positive Lung Cancer
November 19, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
Briefs
Phase 2 Trial
Non/Small Cell Lung Cancer
From
Benzinga
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
November 18, 2021
Tickers
ALNY
BIIB
BMRN
DRNA
Tags
Long Ideas
Rumors
BIIB
From
Benzinga
Spark Therapeutics' Hemophilia Gene Therapy Shows Reduction In Bleeding Episodes
November 18, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
News
Phase 1 Trial
General
From
Benzinga
Atea Shares Plunge As Roche Culls Partnership To Develop COVID-19 Pill
November 17, 2021
Tickers
AVIR
RHHBF
RHHBY
RHHVF
Tags
Phase 3 Study
AVIR
Briefs
From
Benzinga
Europe Approves Regeneron - Roche's COVID-19 Antibody Cocktail
November 12, 2021
Tickers
REGN
RHHBF
RHHBY
RHHVF
Tags
News
General
REGN
From
Benzinga
EU Regulator Backs Regeneron-Roche's COVID-19 Drug
November 11, 2021
Tickers
REGN
RHHBF
RHHBY
RHHVF
Tags
Market News
RHHVF
Health Care
From
Benzinga
Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters
November 10, 2021
Tickers
BIIB
LLY
RHHBF
RHHBY
Tags
RHHBF
Biotech
RHHBY
From
Benzinga
ALX Oncology Falls After Updated Data For Solid Tumors Candidate
November 09, 2021
Tickers
ALXO
MRK
RHHBF
RHHBY
Tags
Briefs
Trading Ideas
MRK
From
Benzinga
Regeneron-Roche's COVID-19 Treatment Shows Long Term Benefit After Single Dose
November 08, 2021
Tickers
REGN
RHHBF
RHHBY
RHHVF
Tags
General
News
Phase 3 Trial
From
Benzinga
Novartis To Offload Its Stake Back To Roche For $20.7B
November 04, 2021
Tickers
NVS
RHHBF
RHHBY
RHHVF
Tags
News
General
RHHVF
From
Benzinga
Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting
November 02, 2021
Tickers
GLTO
RHHBF
RHHBY
RHHVF
Tags
RHHBF
Benzinga
RHHBY
From
Benzinga
Roche Expects Higher FY21 Sales As Delta Variant Boosts Demand For Diagnostics
October 20, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
RHHVF
Market News
Health Care
From
Benzinga
AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial
October 20, 2021
Tickers
ABBV
AMGN
AZN
AZNCF
Tags
Briefs
AZN
News
From
Benzinga
Why Are Atea Pharmaceuticals Shares Plunging Today?
October 19, 2021
Tickers
AVIR
RHHBF
RHHBY
RHHVF
Tags
Biotech
RHHBY
why it's moving
From
Benzinga
Roche's Tecentriq Wins FDA Approval In Adjuvant Lung Cancer Setting
October 18, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
Benzinga
RHHBY
FDA
From
Benzinga
Roche's Alzheimer's Candidate Secures FDA Breakthrough Designation
October 08, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
Benzinga
Biotech
FDA
From
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.